Moreover, the opioid system plays a critical role in maintaining GI homeostasis, and, because of that, targeting of the endogenous opioid system with NEP inhibitors may be a promising therapeutic strategy for the treatment of IBD. This evidence concerns the gene MME and inflammatory bowel disease.